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Abstract: With the introduction of next generation sequencing methods, such as RNA sequencing,
it has become apparent that alterations in the non-coding regions of our genome are important
in the development of cancer. Particularly interesting is the class of long non-coding RNAs
(lncRNAs), including the recently described subclass of circular RNAs (circRNAs), which display
tissue- and cell-type specific expression patterns and exert diverse regulatory functions in the cells.
B-cells undergo complex and tightly regulated processes in order to develop from antigen naïve cells
residing in the bone marrow to the highly diverse and competent effector cells circulating in peripheral
blood. These processes include V(D)J recombination, rapid proliferation, somatic hypermutation and
clonal selection, posing a risk of malignant transformation at each step. The aim of this review is to
provide insight into how lncRNAs including circRNAs, participate in normal B-cell differentiation,
and how deregulation of these molecules is involved in the development of B-cell malignancies.
We describe the prognostic value and functional significance of specific deregulated lncRNAs in
diseases such as acute lymphoblastic leukemia, chronic lymphocytic leukemia, mantle cell lymphoma,
diffuse large B-cell lymphoma, follicular lymphoma, Burkitt lymphoma and multiple myeloma,
and we provide an overview of the current knowledge on the role of circRNAs in these diseases.
Keywords: long non-coding RNA; circular RNA; B-cell development; mantle cell lymphoma (MCL);
acute lymphoblastic leukemia (ALL); chronic lymphocytic leukemia (CLL); diffuse large B-cell
lymphoma (DLBCL); burkitt lymphoma (BL); multiple myeloma (MM); gene regulation
1. Introduction
Long non-coding RNA (lncRNA) comprises a large and heterogeneous class of transcripts,
arbitrarily defined as being more than 200 nucleotides in length, and generally characterised by low
sequence conservation. However, some lncRNAs are evolutionary conserved with preserved functions,
and the fact that negative selection acts on the promoters of these transcripts underlines the fact that
they are strictly regulated and functionally important [1]. In humans, more than 20,000 protein-coding
genes account for less than 3% of the entire genome, while approximately 80% has been shown
to be non-coding, but functional [2]. According to the latest GENCODE update, 15,778 lncRNA
transcripts have been annotated [3], and expression of lncRNAs, that are mainly localised in the
nucleus, are generally lower and more tissue-specific than messenger RNAs (mRNAs) [4]. For a
positional categorisation based on the GENCODE catalogue of lncRNAs, see Figure 1 [4,5]. Note that
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lncRNA terminology is often conflicting and overlapping, and currently, an unambiguous system
for annotation of lncRNAs does not exist. For further insights into these difficulties of lncRNA
classification, annotation, and terminology, we refer to Wright et al. and Laurent et al. [6,7].
LncRNAs exert diverse functions such as chromatin remodelling, transcriptional regulation
and posttranscriptional processing [8–10]. For instance, homeobox transcript antisense intergenic RNA
(HOTAIR) regulate gene expression by serving as a scaffold for histone modification enzymes [11],
and large intergenic non-coding RNA p21 (lincRNA-p21) can serve as a transcriptional coactivator or
repressor [12,13]. Nuclear enriched abundant transcript 1 (NEAT1) participates in nuclear retention
of mRNAs [14], and metastasis associated lung adenocarcinoma transcript 1 (MALAT1) is involved in
alternative splicing [15]. In the cytoplasm, lncRNAs can act as decoys, inhibiting protein synthesis
of host genes [16], or regulating the translation of specific transcripts, which has been shown for
growth-specific 5 (GAS5) [17]. See Figure 2.
A newly recognised subclass of lncRNA, named circular RNA (circRNA), have emerged as important
gene regulatory molecules. CircRNAs are formed through a backsplicing event, which covalently link the
3′ end of an exon to the 5′ end of the same or an upstream exon. Most circRNAs originate from a host
gene, and their biogenesis is facilitated either by flanking homologous inverted repeats bringing the
splice sites in close proximity, or by dimerization of RNA binding proteins [18,19].
These molecules also display tissue- and disease-specific expression patterns, but, unlike other
lncRNAs, many circRNAs are highly evolutionary conserved [18,20]. Due to the lack of free ends,
circRNAs are highly stable molecules that are resistant to exonucleases [18], and thus they hold great
potential as diagnostic and prognostic biomarkers. It has been shown that particular circRNAs function
as direct or indirect regulators of host gene expression at the transcriptional level [21,22], as sponges of
microRNAs (miRNAs) [23,24], as protein scaffolds [25], or as specific or global regulators of protein
translation [26,27]. Recent studies have reported that some circRNAs under certain circumstances
can serve as templates for translation [28–31], yet the vast majority of circRNAs are considered to be
non-coding [32]. See Figure 3.
Several studies have shown that lncRNAs and circRNAs are involved in cell differentiation and
tissue development [33–36], and they are central players in the pathogenesis of various diseases
including cancer [37–40]. However, regarding B-cell malignancies, only a limited number of studies
have examined the role of lncRNAs and circRNAs as drivers of carcinogenesis, and assessed whether
strict regulation of these molecules is necessary for normal B-cell differentiation. For a comprehensive
review on B-cell development and a description of how different subtypes of lymphoma are proposed
to arise from different stages of B-cell maturation, we refer to Küppers et al. [41].
In this review, we provide an overview of the current studies examining the expression and
functions of lncRNAs and circRNAs in B-cell development and oncogenic transformation into various
B-cell malignancies.
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Figure 1. Positional classification of long non-coding RNAs (lnc) according to the GENCODE v7 catalogue of human long non-coding RNAs. (a) Intergenic long
non-coding RNAs (lncRNAs) are located in between two independent genes and can be transcribed either from the same strand (1) or antisense in a divergent (2) or
convergent (3) manner. (b) Genic lncRNAs are subdivided into: (1) exonic lncRNAs that intersect a protein-coding gene by at least 1 bp, (2) intronic lncRNAs that
reside within the intron of a protein coding gene as either sense or antisense, and (3) overlapping lncRNAs that contain a protein-coding gene within an intron, as either
sense or antisense. All antisense transcripts can be transcribed in a head-to head manner, as shown in (2), or in a tail-to-tail manner, as shown in (1). Arrows indicate
direction of transcription of the protein-coding gene (blue) or the lncRNA (green). A final category is termed “processed transcript”, and this is used when the locus
does not contain an open reading frame, but it does not fall into any of the other categories.
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Figure 2. Cellular functions of lncRNAs. (a) LncRNAs as scaffolds for histone modification enzymes. Homeobox transcript antisense intergenic RNA (HOTAIR) tethers
both polycomb repressive complex 2 (PRC2) and coREST/REST/LSD1, thereby specifying the pattern of histone modification on target genes. (b) lncRNAs can
regulate gene expression in cis or in trans. Shown here is large intergenic non-coding RNA p21 (lincRNA-p21), which act in cis as a coactivator for p53-dependent
transcription of p21, or in trans by interacting with heterogenous nuclear ribonucleoprotein K (hnRNP-K) to mediate repression of distant p53 target genes (c) LncRNAs
such as nuclear enriched abundant transcript 1 (NEAT1) can retain mRNAs in the nucleus by associating with paraspeckle proteins such as PSF, PSP1, and p54. (d) In
tissue-specific alternative splicing, lncRNAs participate by recruiting serine/arginine splicing factors (SR) to nuclear speckles, and thereby to the target pre-mRNAs,
as shown for metastasis associated lung adenocarcinoma transcript 1 (MALAT1). (e) LncRNAs can serve as decoys inhibiting protein synthesis, here exemplified by
antisense lncRNA PU.1, which blocks transfer RNA (tRNA) recruitment by inhibiting elongation through translation elongation factor eEF1a1, thereby inhibiting
hematopoietic transcription factor PU.1 mRNA translation. (f) LncRNA growth-specific 5 (GAS5) interacts with translation initiation factor eIF4E to suppress the
translation of c-myc mRNA.
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Figure 3. Proposed functions of circular RNAs (circRNAs). (a) CircRNAs can regulate gene expression indirectly through competition with canonical splicing.
(b) Exon-intron circular RNAs (EICircRNAs) can directly enhance the transcription of host genes through interaction with the transcription complex. (c) CircRNAs
can function as microRNA (miRNA) sponges, here exemplified by circular sponge for miR-7 (ciRS-7), which has >70 binding sites for miR-7. In the presence of
ciRS-7, miR-7 target mRNA will be released from the miRNA-mediated repression. Upon binding of miR-671, an argonaute 2 (AGO2)-mediated cleavage occurs,
providing immediate activation of miR-7 (d) CircRNAs can function as protein scaffolds or decoys. CircFOXO3 forms a ternary complex with p21 and cyclin-dependent
kinase 2 (CDK2), blocking the interaction with cyclin A and cyclin E, thereby retarding cell cycle entry. (e) CircRNAs can serve as specific or global regulators of
protein translation. CircRNA polyadenylate-binding protein nuclear (PABPN) sequesters the RNA-binding protein Hu Antigen R (HuR), leading to decreased PABPN
mRNA translation. (f) Under certain circumstances, circRNAs have been reported to be translated.
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2. LncRNA in B-Cell Development
LncRNA expression profiling during B-cell development has been performed in several studies
that report cell-type specific expression patterns at various stages of B-cell development [42–47].
Specifically, one study reported expression of antisense lncRNAs such as MYB-AS1, SMAS-AS1,
and LEF-AS1 originating from protein-coding genes with known functions in B-cell development,
and a lincRNA named CTC-436K13.6, in early B-cell subsets [44].
Furthermore, the cells in proliferative stages of B-cell development, including both precursor
B-cells and centroblasts in the germinal centres (GC), showed co-expression of mitotic cell cycle genes
with several lncRNAs including the bidirectional lncRNA named colorectal neoplasia differentially
expressed (CRNDE) [44]. Tayari et al. only examined mature B-cell populations and reported similar
expression profiles of lncRNAs in naïve and memory B-cell subsets, but significant differential
expression in the cells of the highly proliferative GC [46], a pattern that was also observed in two
other profiling studies [43,47], suggesting that lncRNAs might play a pivotal role here. A study in
mice reported that expression of paired box 5 (PAX5), a transcription factor that is crucial for B-cell
commitment [48], led to differential expression of several lncRNAs, including enhancer-associated
lncRNAs, which were shown to be bound by PAX5, and for which human orthologs have been
described [47]. Another study in mice proposed a dominant role of germ-line transcribed lncRNAs
during V(D)J recombination in progenitor B-cells [49]. The most abundant transcripts were
the PAX5-activated intergenic repeat (PAIR) elements PAIR4 and PAIR6, which are transcribed
antisense to PAX5. The authors propose that these lncRNAs are essential for locus compaction,
positioning neighbouring heavy chain genes optimally for gene rearrangements to occur [49].
Remarkably, B-cells that are deficient of the transcription factor YY1, which is necessary for distal
VH gene rearrangements and precursor B-cell transition [50], displayed a marked reduction in both
antisense transcription and DNA looping between the PAIR promoter and the intronic enhancer,
compared to B-cells with intact YY1 [49], supporting a pivotal role of PAIR4 and PAIR6 in V(D)J
recombination during B-cell development. YY1 has also been proposed to interact with and relocate
the lncRNA Xist, to the inactivated X-chromosome in activated B-cells, thereby changing the X-linked
gene regulation in these cells compared to antigen naïve B-cells [51].
Finally, high levels of the protein-coding PU.1 result in macrophage development, while low
levels lead to B-cell commitment [52]. In mice, high PU.1 expression levels are necessary for the
transition of B1 to B2 cells, and since failure to perform this lineage commitment has been linked to
malignant transformation [53], the antisense PU.1 could be a driver of lymphomagenesis by inhibiting
the expression of PU.1 at the translational level [16].
3. Long Non-Coding RNA Expression in Various B-Cell Malignancies
With the development and wide accessibility of high-throughput technologies such as RNA
sequencing (RNA-seq) [54], it has become evident that deregulation in the non-coding regions of our
genome play a pivotal role in oncogenic transformation [39]. Here, we provide an overview of the
current knowledge on expression and function of lncRNAs in B-cell malignancies, based on disease
entities. Table 1 lists the lncRNA candidates, which have been examined by more than one study,
and provide an overview of the functional characterisation and prognostic value of these lncRNAs
across various B-cell malignancies.
3.1. Acute Lymphoblastic Leukemia
In B-cell acute lymphoblastic leukemia (B-ALL), a specific lncRNA expression pattern was
observed in patients with MLL-rearranged B-ALL, compared to normal controls and to B-ALL patients
without rearrangements [55]. The MLL gene is associated with adverse outcome [56], and the lncRNA
expression pattern could stratify patients based on the MLL fusion partner. In a larger study, a lncRNA
signature could predict whether patients carried the cytogenetic subtype EVT6-RUNX1, TCF3-PBX1 or
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MLL rearrangements, and these transcripts were therefore termed B-ALL-associated long non-coding
RNAs (BALR). The most differentially expressed lncRNAs between leukemic and normal B-cells and
within the cytogenetic subtypes were BALR-1, BALR-2, BALR-6, and LINC00958 [57], and interestingly,
both BALR-2 [57] and BALR-6 [58] knockdown increased apoptosis. The expression of the lincRNA
CASC15, which is located adjacent to the transcriptional activator SOX4, was significantly higher
expressed in patients with EVT6-RUNX1 and TCF3-PBX1 translocations than in patients with MLL
rearrangements [57]. Expression of CASC15 and SOX4 was positively correlated, and functional studies
suggested that CASC15 could enhance the transcription of SOX4 through YY1 [59]. Furthermore,
the expression of four lncRNAs, lnc-NKX2-3-1, lnc-RTN4R, lnc-TIMM21-5, and lnc-ASTN1-1, was shown
to be specifically regulated by the oncogenic fusion protein EVT6/RUNX1 [60], which is known to be
associated with favourable prognosis [61]. In order to explore previously unannotated transcripts,
one study used RNA-seq and identified 799 lncRNAs deregulated in B-ALL compared to controls [62].
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Table 1. LncRNAs with prognostic and/or functional impact in B-cell malignancies verified by more than one study.
Name Samples * Expression Proposed Function Prognostic Impact Reference
BALR-1 118 B-ALL ↑ No functional studies No association with PFS/OS [57]
56 B-ALL ↑ No functional studies No association with PFS/OS [62]
BALR-2 118 B-ALL, cell lines ↑
Promote cell survival via the inhibition of genes such as
the proapoptotic BIM downstream of the
glucocorticoid receptor
↑ in steroid resistant patients and
patients with poor OS [57]
56 B-ALL ↑ No functional studies No association with PFS/OS [62]
BALR-6 118 B-ALL, cell lines, mice ↑
Promotes cell survival and inhibits apoptosis.
Overexpression in mice leads to an increase in precursor
cell populations
No association with PFS/OS [57,58]
LINC00958 118 B-ALL ↑ No functional studies No association with PFS/OS [57]
56 B-ALL ↑ No functional studies No association with PFS/OS [62]
MALAT1 40 MCL, cell lines ↑ Binds to EZH2 and induces transcriptional repression oftargets such as p21 and p27 High vs. low expression: HR = 3 [63]
DLBCL cell lines, xenograft mice ↑ KD induces the expression of autophagy-relatedproteins, improving chemotherapy-sensitivity Not assessed [64]
33 SMM, 170 MM, 36 PCL ↑ Associated with TP53-mediated DNA damage response Not assessed [65]
36 MM ↑ No functional studies Change in expression (diagnosis/treatment) associated with PFS [66]
lincRNA-p21 73 primary CLL cells ↑ in TP53
wt compared to
TP53del/mut
Decrease cell viability in a p53-dependent manner upon
DNA damage Not assessed [67]
68 CLL plasma samples ↓ p53 dependent cis-upregulation of p21, leading to cellcycle control through interaction with PRC2 Not assessed [12,68]
NEAT1 73 primary CLL cells ↑ in TP53
wt compared to
TP53del/mut Nuclear retention of mRNAs with inverted repeats Not assessed [14,67]
51 MM, cell lines ↑ Binds to miR-193a leading to MCL-1 upregulation andsteroid resistance ↑ in patients with poor OS [69]
MIAT 67 CLL, cell lines ↑ in patients with bad outcome KD of MIAT, or its positive regulator OCT4,induces apoptosis ↑ in patients with poor OS [70]
30 MM ↓ in patients with t (11;14) Involved in alternative splicing [71,72]
CRNDE 70 CLL ↓ Interacts with PRC2 and CoREST to modulatetranscriptional repression
Promoter methylation associated
with poor OS [73,74]
77 MM, cell lines ↑ Binds to miR-451 to induce proliferation andinhibit apoptosis ↑ in patients with poor OS [75]
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Table 1. Cont.
Name Samples * Expression Proposed Function Prognostic Impact Reference
NAALADL2-AS2 10 DLBCL, cell lines ↑ Involved in p53, NFκB, and JAK/STAT signallingpathways (Gene Ontology Analysis) Not assessed [76,77]
HOTAIR 50 DLBCL, cell lines ↑ Cell cycle progression and apoptosis inhibition throughPI3K/AKT/NFκβ pathways
↑ in patients with poor OS.
HOTAIR > median vs. < median:
HR = 3.1
[78]
164 DLBCL Not specified Recruits PRC2 and induce silencing of target genesthrough H3K27me3
↑ (higher than cancer-free tissue)
in patients with favourable OS [79,80]
GAS5 33 SMM, 170 MM, 36 PCL ↑ in patients with 1q gain lesions No functional studies Not assessed [65]
MCL cell lines KD reduces apoptosis and decreases the effects ofmTOR inhibitors on cell viability Not assessed [81]
MCL cell lines GAS5 interact with c-myc mRNA to reduce translation Not assessed [17]
UCA1 84 MM ↓ No functional studies High vs. low expression: HR = 2 [82]
60 MM, cell lines ↑ Involved in cell proliferation and inhibition of apoptosis Not assessed [83]
H19 30 MM ↑ Induce proliferation through NFκβ pathway H19 ↑ in patients with poor PFS [84]
80 MM ↑ No functional studies [85]
* The number of patient samples included are shown and/or the species in which any functional studies were carried out. ↑ designates significantly elevated expression levels, while ↓
designates significantly decreased expression levels compared to normal controls unless otherwise specified. Not assessed denotes that the prognostic significance of the lncRNA was not
assessed in the specific study. Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; MCL, mantle cell lymphoma; DLBCL, diffuse Large B-cell lymphoma; SMM, smoldering multiple
myeloma; MM, multiple myeloma; PCL, plasma cell leukemia; CLL, chronic lymphocytic leukemia; KD, knockdown; PFS, progression-free Survival; OS, overall survival; HR, hazard Ratio.
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These lncRNAs were more B-ALL-subtype specific than protein-coding genes and of note,
this study confirmed the study by Fernando et al. [57], showing upregulation of BALR-1 and LINC00958
and increased BALR-2 expression in patients with EVT6/RUNX1 and MLL rearrangements, respectively.
It was also shown that one of the upregulated lncRNAs, RP11-137H2.4 [62], reduced cell-proliferation,
increased apoptosis upon cytotoxic treatment, and partly restored sensitivity to prednisolone in
resistant cell lines [86].
Finally, the methylation patterns of CpG islands in antisense lncRNA coding regions have been
examined, showing significant hypermethylation within the gene bodies of antisense lncRNAs in
ALL compared to progenitor B-cells, yet expression levels of these lncRNAs were not examined [87].
This hypermethylation was also observed in naïve B-cells and precursor B-cells, questioning whether
the differential methylation patterns were disease-specific or just related to the maturation states of
the B-cells.
3.2. Chronic Lymphocytic Leukemia
The expression of several lncRNAs has been shown to be regulated by TP53 [88], the deletions
of which are associated with adverse outcome in patients with chronic lymphocytic leukemia (CLL) [89].
Recently, a study showed that lincRNA-p21 is upregulated upon irradiation in cultured primary CLL
cells with wild type TP53, leading to decreased cell viability, a mechanism lacking in cells with TP53
mutations or deletions [67]. Interestingly, the level of cell-free circulating lincRNA-p21 has been shown
to be significantly lower in CLL patients compared to controls, suggestive of tumour-suppressive
functions of lincRNA-p21 [68].
Myocardial infarction-associated transcript (MIAT), a lncRNA involved in RNA splicing [71],
has been correlated with adverse outcome in CLL [70]. Two lncRNAs, DLEU1 and variant DLEU2,
originate from the chromosomal region 13q14.3, which is frequently deleted in CLL, an alteration that
is associated with adverse outcome [90]. DLEU1 and variant DLEU2 are hypomethylated at the 5’-ends,
and upregulated in CLL cells compared to B-cells from controls. On the contrary, the protein-coding
genes, including the DLEU2 region containing the miR15a/16.1 cluster, were downregulated in CLL
cells. The inverse relationship of this gene cluster with DLEU1 and variant DLEU2 suggests that they act
in cis and take part in a multi-regulatory network of protein-coding genes, lncRNAs, and microRNAs
(miRNAs) that might be involved in CLL pathogenesis [91].
DNA methylation levels of the promoter regions of two lncRNAs, AC012065.7, and CRNDE,
have been shown to be inversely correlated with their expression levels. Compared to normal controls,
CLL samples displayed higher methylation levels of the CRNDE promoter, and lower methylation
levels of the AC012065.7 promoter, both associated with poor overall survival (OS) [73]. Moreover,
expression of AC012065.7 and CRNDE were positively correlated with expression of the protein-coding
genes GDF7 and IRX5 respectively; both are encoded close to the lncRNAs, suggesting cis-regulation.
Epigenetic silencing was also shown for the lncRNA named BM742401, which is embedded in
a CpG island. The promoter of this lncRNA was methylated in CLL cell lines, and unmethylated in
bone-marrow samples from normal controls. Treatment with the hypomethylating agent 5-Aza-2’-
deoxycytidine led to an increase in expression levels of BM742401, and overexpression in CLL cell lines
reduced cellular proliferation and enhanced the intrinsic apoptotic pathway. However, in diagnostic
CLL bone marrow samples, the methylation status of BM742401 was not correlated with disease stage
or OS [92].
Ronchetti et al. identified a lncRNA classifier consisting of 24 differentially expressed lncRNAs
that could accurately discriminate CLL patients in early stage (Binet A) from normal controls [93].
Furthermore, it was found that expression levels of two of these lncRNAs, lnc-IRF2-3 and
lnc-KIAA17554, were significantly associated with progression-free survival (PFS) independent of
common risk factors such as NOTCH and IGHV mutational status, CD38 and ZAP70 expression levels,
and chromosomal aberrations.
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Another large RNA-seq experiment showed differential expression of 127 lncRNAs and
61 pseudogenes in CLL compared to controls. The pseudogenes CD24P4 and PSMD10P1, which have
corresponding protein-coding genes involved in B-cell activation and oncogenesis, respectively,
were both upregulated; however, the functions of these molecules remain to be examined [94].
A microarray study identified eight lncRNAs differentially expressed in CLL patients compared
to controls. One of these, translation regulatory long non-coding RNA1 (treRNA1) was significantly higher
expressed in unmutated IGHV samples [95], and served as an independent prognostic marker for
shorter PFS in patients receiving fludarabine and cyclophosphamide. Overexpression of treRNA1 in a
CLL cell line led to reduced cell death, suggesting that treRNA1 decreases DNA damage and sensitivity
to chemotherapy, thereby explaining the shorter PFS. Recently, high expression of an antisense lncRNA
from ARHGAP15 termed AC092652.2-202 was shown to be associated with shorter time to treatment
in CLL patients. This effect was independent of IGHV mutational status and disease stage, and gene
set enrichment analysis showed that genes potentially modulated by this lncRNA were significantly
enriched in the NFκB, apoptosis, and p53 pathways [96].
3.3. Mantle Cell Lymphoma
MALAT1 is upregulated in tumour tissues from mantle cell lymphoma (MCL) patients compared
to normal B-cells, and knockdown of MALAT1 results in cell cycle arrest due to upregulation of
p21 and p27 through enhancer of zeste homolog 2 (EZH2), a component of the polycomb repressive
complex 2 (PRC2) [63]. The non-selective pan-histone deacetylase inhibitor Panobinostat [97] and
the global histone methylation inhibitor 3-deazanoplanocin A (DzNep) [98] act synergistically to
deplete EZH2 and induce apoptosis in primary MCL cells in vitro [99]. Yet, only Panobinostat has been
investigated and it showed activity in patients with MCL; unfortunately however, the treatment led to
severe thrombocytopenia [100], and it is intriguing whether MALAT1 could serve as an alternative
therapeutic target. EZH2, which is upregulated in MCL [101], and linked to adverse outcome [102],
has been shown to bind a lncRNA termed ROR1-AS1, which increases cell proliferation in MCL cell
lines; however, ROR1-AS1 expression was not significantly different when comparing MCL patients
to normal controls [103]. The promoter region of FAS-AS1 is regulated by EZH2 as well, and this
lncRNA serves to modulate alternative splicing of the FAS gene, a central molecule in the extrinsic
apoptosis pathway. FAS-AS1 sequesters RBM5, leading to decreased exon skipping and upregulation
of the membrane-bound isoform, whereas the soluble isoform (sFAS) that inhibits apoptosis,
is downregulated [104]. Treatment with DzNep or Ibrutinib, which targets BTK, increased FAS
ligand-mediated apoptosis in lymphoma cell lines by abolishing the EZH2-mediated repression of
FAS-AS1 expression, leading to decreased expression of sFAS.
It is well established that MALAT1 has oncogenic functions in various cancer types [105],
and depletion of MALAT1 leads to TP53 upregulation, possibly due to double-stranded DNA
damage [106], indicating that TP53 might be a target of MALAT1 as well. Finally, knockdown of
the proposed tumour-suppressor GAS5 resulted in decreased levels of apoptosis in MCL cell lines,
and a significant decrease in the treatment effect of mTOR inhibitors [81].
3.4. Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
One study examined RNA-seq data sets of diffuse large B-cell lymphoma (DLBCL) and showed
that normal tissue displayed the highest average number of lncRNAs per sample, followed by tumour
samples and cell lines, suggesting that expression of lncRNAs might be negatively correlated to the
proliferation states of the cells [107]. In total, 2632 novel lncRNAs were identified in this study, most of
which were only expressed in malignant cells.
Using microarrays, another study identified 1648 upregulated and 2671 downregulated lncRNAs in
germinal centre B-cell (GCB)-DLBCL cell lines compared to normal B-cells [76]. The expression patterns
of five of these lncRNAs (AFAP-AS1, OR2A1-AS1, NAALADL2-AS2, HOTAIRM1, and RP4-545C24.1.)
were confirmed in clinical samples from GCB-DLBCL patients and lymph nodes from normal controls
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by RT-qPCR. A similar approach was used to study differentially expressed lncRNAs between normal
B-cells and DLBCL cell lines of both activated B-cells (ABC- and GCB-type) [77]. Interestingly, one of
the candidates from the other study, NAALADL2-AS2, was also among the most upregulated lncRNAs
in this study; however, no functional studies were performed.
By analysing microarray data from the gene expression omnibus (GEO) database, including more
than 1000 DLBCL patients, a lncRNA signature based on expression of six lncRNAs, SACS-AS1,
MME-AS1, CSMD2-AS1, RP11-360F5.1, RP1125K19.1, and CTC-467M3.1, was significantly correlated
with OS in two independent patient cohorts [108]. Interestingly, the signature could improve risk
stratification by predicting the survival of patients with identical international prognostic index (IPI)
scores. In another study, the same authors reanalysed the data sets and reported a novel signature
consisting of 17 lncRNAs, which could, not only predict OS and PFS, but also distinguish ABC and
GCB subtypes of DLBCL with more than 90% accuracy [109].
It has also been suggested that lncRNAs may play a crucial role in the chromosome breaks
involved in typical gene rearrangements in hematologic malignancies. For example, the boundaries of
the antisense lncRNA RP11-211G3.3.1-1 from the BCL6 locus, precisely match the boundaries of the
BCL6 translocation zone [110], and future studies should assess whether knockdown of this lncRNA
could prevent BCL6 translocation and potentially preclude lymphoma development.
Several studies have examined the prognostic significance of single lncRNAs in DLBCL.
A promising candidate, HOTAIR, repress target genes through PRC2 [80], and two studies reported
diverging results regarding the association of HOTAIR expression with OS [78,79]. Another study
found that P21-associated non-coding RNA (ncRNA) DNA damage activated (PANDA) was downregulated
in DLBCL samples compared to normal controls, and low expression was associated with poor OS.
Mechanistically, PANDA was shown to be activated by p53, and downregulation of PANDA increased
cell viability in DLBCL cells, whereas overexpression had the opposite effect [111]. MALAT1 has
also been proposed to play a role in DLBCL oncogenesis [64], yet expression levels have not been
analysed in DLBCL patients. High expression of a lncRNA originating as a processed transcript from
paternally expressed 10 (PEG10) has also been associated with decreased OS in DLBCL, and knockdown
was shown to induce apoptosis in a DLBCL cell line [112]. Another lncRNA, NONHSAG026900
was significantly lower expressed in DLBCL compared to normal B-cells in two independent patient
cohorts, and expression levels could add predictive power to the IPI score, yet it was inferior to IPI
when used as an independent prognostic marker [113].
In follicular lymphoma (FL), only one small study has examined lncRNA expression, and showed
that 189 lncRNAswere aberrantly expressed between three patients with grade 3a FL and normal
controls. Four candidates were validated with RT-qPCR, and RP11-625 L16.3 and CTC-546 K23.1 were
significantly upregulated, whereas AP005530.2 and AP005530.2 were significantly downregulated [114].
3.5. Burkitt’s Lymphoma
In Burkitt’s lymphoma (BL), translocations involving the proto-oncogene MYC and one of the three
immunoglobulin loci are considered a pathogenic hallmark [115,116]. A comprehensive study analysed
RNA-seq data and showed that a lncRNA that was transcribed from chromosome 8 was significantly
correlated with MYC expression, and the authors termed it MYC-induced long non-coding RNA (MINCR).
The association of MYC and MINCR seemed to represent a general oncogenic mechanism, since it
could also be detected in DLBCL, FL, CLL, and non-haematological cancers [117]. Upon MINCR
knockdown, expression of cell-cycle related genes such as AURKA, AURKB, and CDT1 was affected,
leading to the perturbation of cell-cycle progression. These genes all displayed decreased MYC-binding
in their promoter regions upon MINCR knockdown, suggesting that this lncRNA was involved in
regulating MYC target genes. Furthermore, it has been proposed that MYC enhances rather that
induces transcription of lncRNAs, since data from a MYC-repressible cell line expressed the same
lncRNAs in the MYC-OFF state and the MYC-ON state, but at significantly different levels. The same
study examined patient samples and identified a total of 974 differentially expressed lncRNAs when
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comparing nine CLL patients and 13 patients with BL, characterised by low and high MYC expression,
respectively [118].
3.6. Multiple Myeloma
Compared to other B-cell malignancies, there are numerous studies on lncRNA expression
in multiple myeloma (MM), including lncRNA profiling by both microarray [65,119–122] and
RNA-seq [72,123]. One of these studies compared normal plasma cells to plasma cells from patients
with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma
(SMM), MM and plasma cell leukemia (PCL), and identified 160 differentially expressed lncRNAs.
These included six lncRNAs that were validated by RT-qPCR, MALAT1, GAS5, DLEU2, lnc-LRRC47-1,
lnc-ANGPTL1-3, and lnc-SENP5-4, the latter three being significantly deregulated in more aggressive
diseases [65].
Interestingly, one of the RNA-seq studies reported that in 30 MM samples, 12 lncRNAs including
NEAT1, MALAT1, MIAT, and taurine upregulated 1 (TUG1) were highly expressed, accounting for 64%
of the reads mapping to lncRNAs [72]. The other RNA-seq study focused specifically on lincRNAs
and determined a risk score based on a lincRNA signature consisting of the 14 lincRNAs with highest
impact on PFS. The signature was validated in an independent cohort and could separate patients
with high and low risk disease, with respect to both PFS and OS [123].
While many specific lncRNAs are proposed to have prognostic relevance in MM [120,122],
even studies examining the same data sets identify different lncRNAs with prognostic
potentials [120,121], and e.g. MALAT1 has been proposed as a prognostic biomarker, yet studies report
diverging results [66,68], emphasising the need for validation studies.
Maternally expressed 3 (MEG3), an imprinted lncRNA transcribed antisense to BMP4, was shown
to promote BMP4-induced osteogenic differentiation of mesenchymal stem cells isolated from bone
marrow samples. The level of MEG3 was significantly lower in MM patients compared to controls [124],
which was suggested to be due to promoter hypermethylation [125]. Promoter hypermethylation
has also been proposed to cause downregulation of KIAA0495 (TP73-AS1) [126] in MGUS and MM
patients, but not in healthy controls [127]. A different antisense lncRNA from the tumour suppressor
gene TP73, has been reported to be downregulated in MM as well [65].
Polymorphisms may also influence the expression of lncRNAs, as is the case for antisense
non-coding RNA in the INK4-ARF locus (ANRIL), which is highly expressed in individuals carrying
TT as compared to CC or CT at the rs2151280 polymorphism. High ANRIL expression results in
lower expression of p15, p14ARF, and p16, possibly explaining why this polymorphism is significantly
associated with poor PFS in MM [128].
Studies have also focused on how lncRNAs interact with miRNAs and influence cellular
processes via downstream signalling pathways. For instance, OIP5-AS1 downregulation has been
shown to result in accumulation of miR-410, which target KLF-10, leading to increased cell cycle
progression, proliferation, and inhibition of apoptosis through the PTEN/PI3K/AKT pathway [129].
Similarly, FEZF1-AS1 act as a competing endogenous RNA (ceRNA) for miR-610, thereby releasing
the miR-610-mediated inhibition of AKT3 [130]. Colon cancer-associated transcript 1 (CCAT1) was also
shown to act as a ceRNA by binding miR-181a-5p, thereby releasing inhibition of HOXA1 expression.
CCAT1 expression was significantly higher in MM patients compared to controls, and knockdown
resulted in suppression of MM tumour growth in MM cell lines and mice [131].
The role of lncRNA in drug response has been investigated as well. Six upregulated and nine
downregulated lncRNAs were identified in both proteasome-inhibitor-resistant MM cell lines and
isolated CD138 cells from MM patients compared to proteasome-inhibitor-sensitive cells or CD138
cells from healthy controls [132].
STAT3, a transcription factor linked to MM oncogenesis [133], has been shown to induce specific
lncRNAs, termed STAT3-induced lncRNAs (STAiRs), upon activation of IL-6. STAiRs included both
nuclear-retained lncRNAs that inhibit tumour-suppressive functions specific for MM, and lncRNAs
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that were ubiquitously expressed in various tumours and seemed to be involved in chromatin
silencing [134].
Other lncRNAs suggested to play a role in MM include NEAT1 [69], MIAT [72], CRNDE [75],
urothelial cancer associated 1 (UCA1) [82,83], H19 [84,85], protein disulfide isomerase family a member 3
pseudogene 1 (PDIA3P), and prostate cancer associated transcript 1 (PCAT1) [135].
4. Circular RNA in B-Cell Development and Malignancies
Studies examining the role of circRNAs in the pathogenesis of B-cell malignancies are very sparse.
The circRNA research field is quite new; however, increasing scientific interest has emerged since the
discovery that ciRS-7 contains approximately 70 binding sites for the proposed tumour-suppressor
miR-7 [23,24], indicating that ciRS-7 could have a central role in tumour development [136]. However,
compared to lncRNAs, circRNAs are more difficult to study, primarily because they lack poly(A) tails,
and they are therefore discarded during library preparation for RNA-seq when using protocols that rely
on a poly(A) purification step for removal of ribosomal RNA (rRNA). Thus, most publicly available
RNA-seq data sets cannot be analysed for circRNA expression, and specific bioinformatic pipelines
recognising the specific backsplicing junction of circRNAs need to be utilised [137]. Furthermore,
substantial methodological challenges like template switching and rolling circle amplification during
RT and amplification bias during PCR have been observed in the detection of circRNAs, and risk
hampering the results [38,138,139].
One of the first studies to profile circRNA expression in both normal and malignant tissues
reported that >700 circRNA candidates were identified in five samples from children with hyperdiploid
B-ALL [20]. Host genes for the most highly expressed circRNAs included ESYT2, FBXW4, CAMSAP1,
KIAA0368, CLNS1A, FAM120A, MAP3K1, ZKSCAN1, MANBA, ZBTB46, NUP54, RARS, and MGA,
and all were confirmed by RT-qPCR using divergent primer design. In normal CD19, positive naïve
B-cells, and CD34 positive hematopoietic stem cells, novel circRNA candidates were identified
as well [20].
No studies have yet examined the role of circRNAs during normal B-cell development and
differentiation; however, specific circRNA signatures characteristic for B-cells compared to T-cells
and progenitors have been described [140]. Intriguingly, studies in mice have also revealed that a
circRNA originating from the D430042O09Rik gene was constitutively expressed, and it was shown to
bind cyclic GMP-AMP synthase (cGAS) to block its enzymatic activity, thereby protecting long-term
hematopoietic stem cells (LT-HSCs) from cGAS-mediated IFN-I-driven exhaustion [141].
It has also been observed that chromosomal translocations can give rise to fusion-circRNAs,
transcribed from exons of distinct genes [142]. For example, two circRNAs are transcribed from the
MLL-AF9 translocation observed in ALL, and both exert oncogenic properties; however, it remains to
be determined whether chromosomal translocations characteristic for other B-cell malignancies also
give rise to fusion-circRNAs. In BL, characterised by high MYC expression as described above,
upregulation of the circRNAs ZDHHC11 and ZDNN11B was shown, along with upregulation
of the MYC target MYB. These circRNAs contain multiple binding sites for miR-150, a miRNA
that was downregulated in cell lines with high MYC expression. The authors proposed that
ZDHHC11 and ZDNN11B act as ceRNAs that bind miR-150 in normal cells to inhibit proliferation,
while in BL cells, the MYC-induced repression of miR-150 leads to increased proliferation through
upregulation of ZDHHC11, ZDNN11B, and MYB [143]. Another circRNA that might be important in
lymphomagenesis is circAmotl1, which has been shown to trigger tumourigenesis through nuclear
translocation of MYC and upregulation of MYC targets [144]; however, no studies have yet examined
whether circAmotl1 is an important oncogenic driver in B-cell malignancies with high MYC expression
such as BL or DLBCL.
Finally, we have recently performed RNA-seq in MM and MCL cell lines to profile the landscape
of circRNA expression in B-cell malignancies [145]. Several circRNAs, previously shown to be
implicated in other cancers were identified, including ciRS-7 [136,146,147], circHIPK3 [148,149],
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circCCDC66 [150], circFBXW7 [31], circSMARCA5 [151,152], circCDYL [149], and circZKSCAN1 [153].
CircRNAs from host genes involved in lymphomagenesis and the development of MM were
also detected, including FOXP1 [154], SETD3 [155], EZH2 [156], ATM [157], XPO1 [158],
CD11A (ITGAL) [159], WHSC1 (MMSET) [160], and IKZF3 [161]; the latter is not listed in circBase [162].
In this study, we also applied a new method for accurate quantification of circRNAs using the
NanoString Technology [163]. This method is free of any enzymatic steps and is therefore less prone to
the introduction of biases relating to RT and amplification steps, and because the technology is based
on two short probes, it is well suited for examining RNA samples isolated from formalin-fixed
paraffin-embedded (FFPE) tissues [164]. We demonstrated that high quality data on circRNA
quantification, in RNA samples isolated from FFPE tissues of patients with various B-cell malignancies,
could be obtained [145].
It is apparent that even though circRNAs are highly expressed in various B-cell malignancies,
it remains to be elucidated whether some circRNAs are independent oncogenic drivers, and what their
mechanisms of action are.
5. Conclusions
It is evident that lncRNAs play important roles in B-cell development and differentiation, and the
tissue- and cell-type-specific distribution makes these molecules promising candidates as prognostic
and diagnostic biomarkers. However, several obstacles preclude the characterisation and clinical use of
these molecules. As briefly touched upon, methodological challenges like PCR amplification bias [165],
and cross-hybridisation issues in microarray [166] can hamper results, and they may explain some of
the divergence in the studies described above. Even though many lncRNA profiling studies have been
carried out, very few lncRNAs with prognostic potential have been identified, and the findings have
rarely been validated in independent patient cohorts.
Regarding characterisation of lncRNAs, the relatively low evolutionary conservation [167] limits
the use of animal models to study their function. Even when performing in vitro loss-of-function
studies using common techniques such as RNA interference (RNAi), numerous difficulties arise.
The nuclear localisation of most lncRNAs makes RNAi less effective [168], and for lncRNAs expressed
at high levels, complete loss-of-function can be hard to obtain [169]. A powerful tool for creating
stable knockouts is the clustered regularly interspaced palindromic repeats (CRISPR) technique [170].
However, researchers have to be cautious when utilising this system for knockdown of lncRNAs,
as it is difficult to avoid affecting the expression of protein-coding genes from the same locus [171].
The ability of lncRNAs and circRNAs to bind miRNAs has fostered the idea that these molecules are
capable of regulating gene expression through the interaction with miRNAs. However, stoichiometric
analyses of lncRNA:miRNA:mRNA ratios and circRNA:miRNA:mRNA ratios are rarely performed,
and the ceRNA hypothesis is only supported for a few candidates with multiple binding sites for
miRNAs in cells with high expression levels of the circRNA or lncRNA [172,173]. In spite of these
challenges, great advancements within the field of lncRNA have been made, and novel techniques
for functional characterisation and computational tools for studying the regulatory crosstalk between
mRNAs, miRNAs, lncRNAs, and circRNAs are evolving [174,175].
When assessing the prognostic value of lncRNAs and circRNAs it is important that identified
candidates are validated in independent patient cohorts. Preferably, RNA-seq should be performed to
be able to identify previously unannotated transcripts, yet this is often limited by the poor quality of
the RNA isolated from patient samples, particularly if these are conserved as FFPE tissue. Furthermore,
one must bear in mind that novel lncRNA and circRNA candidates identified by RNA-seq need to
be thoroughly validated, as this method is prone to the introduction of bias and artefacts through
the RT and PCR amplification steps. Because of this, the NanoString technology, which is free of
any enzymatic steps, holds great potential as a clinically applicable method for lncRNA [176] and
circRNA [145] quantification.
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In conclusion, lncRNAs, including circRNAs, play pivotal roles in B-cell development and
oncogenic transformation, yet we are only beginning to understand the functions of these molecules
and how they contribute in the fine-tuning of gene expression in normal and malignant tissues.
Future studies should aim primarily at the functional characterisation of these molecules and to
identify suitable biomarkers and therapeutically relevant targets.
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ABC-DLBCL Activated B-cell diffuse large B-cell lymphoma
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B-ALL B-Cell Acute lymphoblastic leukemia
BALR B-ALL-associated long non-coding RNAs
BL Burkitt Lymphoma
CCAT1 Colon cancer associated transcript 1
ceRNA Competing endogenous RNA
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ciRS-7 Circular RNA sponge for miR-7
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FFPE Formalin-fixed paraffin-embedded
FL Follicular lymphoma
GAS5 Growth specific 5
GC Germinal center
GCB-DLBCL Germinal center diffuse large B-cell lymphoma
GEO Gene expression omnibus
HOTAIR The HOX transcript antisense intergenic RNA
IPI International prognostic index
KD Knockdown
lincRNA-p21 Large intergenic non-coding RNA p21
lncRNA Long non-coding RNA
LT-HSCs Long term hematopoietic stem cells
MALAT1 Metastasis associated lung adenocarcinoma transcript 1
MCL Mantle cell lymphoma
MIAT Myocardial infarction associated transcript
MINCR MYC-induced long non-coding RNA
miRNA MicroRNA
MEG3 Maternally expressed 3
MGUS Monoclonal gammopathy of undetermined significance
MM Maternally expressed 3
NEAT1 Nuclear enriched abundant transcript 1
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OS Overall survival
PAIR PAX5 activated intergenic repeat
PANDA P21 associated ncRNA DNA damage activated
PCAT1 Prostate cancer associated transcript 1
PEG10 Paternally expressed 10
PFS Progression-free survival
PCL Plasma cell leukemia
PDIA3P Protein disulfide isomerase family A member 3 pseudogene 1
PRC2 Polycomb repressive complex 2
RNAi RNA interference
RNA-seq RNA sequencing
rRNA Ribosomal RNA
SMM Smoldering multiple myeloma
STAiRs STAT3-induced lncRNAs
treRNA1 Translation regulatory long non-coding RNA1
TUG1 Taurine upregulated 1
UCA1 Urothelial cancer associated 1
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